Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab in Immunocompromised Japanese Children
NCT01466062Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2011
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of palivizumab in respiratory syncytial virus infection (RSV), sponsored by AbbVie Inc.. Started Aug 2011; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT01466062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466062.